M
MaaT Pharma
Develops a series of microbiome-based drugs targeting mortality and comorbidities associated with blood cancer treatments
About MaaT Pharma
MaaT Pharma is a late-stage clinical biotechnology company that was founded in 2014 in Lyon, France. The company is focused on developing microbiome-based therapies to improve outcomes for cancer patients.
Read full description
MaaT Pharma's approach is to use the gut microbiome to modulate the immune system. The company has developed a proprietary platform, called MaaT Microbiome Restoration Biotherapeutics (MMRB), to create standardized, high-diversity microbiome drug candidates. This platform utilizes pooling and co-cultivation technologies to ensure the consistency and quality of its products.
The company's lead product candidate, MaaT013, is in late-stage clinical development for the treatment of acute Graft-versus-Host Disease (aGvHD), a life-threatening complication of allogeneic hematopoietic stem cell transplantation. MaaT Pharma is also developing MaaT033, a second-generation product candidate, for the prevention of complications after allogeneic hematopoietic stem cell transplantation.
MaaT Pharma's business model is focused on the development and commercialization of its microbiome-based therapies. The company generates revenue through a combination of research and development collaborations, licensing agreements, and product sales. MaaT Pharma is publicly traded on the Euronext Paris stock exchange under the ticker symbol MAAT since 2021.
At a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Lyon, France
- Listing
- IPO 2021
- Employees
- 82
- Open positions
- None listed
- Dealroom signal
- 72.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Hard Tech
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Nov 2025 | $10M | — | Undisclosed | ↗ |
| POST IPO DEBTDebt | Jul 2025 | $41M | — | European Investment Bank | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $11M | +115.5% | −$31M | -286.1% |
| 2025 | $5M | +40.7% | −$31M | -620.4% |
| 2024 | $3.5M | +44.3% | −$29M | -819.2% |
| 2023 | $2.5M | +55.8% | −$20M | -827.8% |
| 2022 | $1.6M | +47.1% | −$14M | -916% |
| 2021 | $1.1M | +9% | −$9.4M | -881.7% |
| 2020 | $981K | — | −$5.6M | -570.4% |
Growth signals
Latest recorded traffic for MaaT Pharma is 6.7K monthly website visits, down 23.9% over the last three months. MaaT Pharma's team grew 1.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
French Government
Series A8 investors entered at this stage
Seventure Partners
Crédit Mutuel Innovation
Crédit Mutuel Equity
BIOCODEX
SymBiosis
Skyviews Life Science
Bpifrance
Celeste Management
Series B and later3 investors entered at this stage
Invus
Tocqueville Asset Management
European Investment Bank
Other known investors5 additional known investors
CNRS Innovation
French National Centre for Scientific Research - CNRS
INRAE
SATT LUTECH
Sorbonne University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MaaT Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MaaT Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.